Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 670.50K | 768.80K | -- | -- | 236.50K |
| Total Other Revenue | -- | -- | 997.80K | -- | -- |
| Total Revenue | 670.50K | 768.80K | 997.80K | 1.25M | 236.50K |
| Cost of Revenue | 169.40K | 200.90K | 353.70K | 372.40K | 115.90K |
| Gross Profit | 501.10K | 567.90K | 644.20K | 878.10K | 120.60K |
| SG&A Expenses | 1.82M | 2.80M | 4.10M | 5.10M | 6.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.22M | 3.98M | 7.61M | 11.03M | 9.88M |
| Operating Income | -1.55M | -3.21M | -6.61M | -9.78M | -9.64M |
| Income Before Tax | -3.36M | -3.49M | -7.76M | -77.25M | -12.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.36M | -3.49M | -7.76M | -77.25M | -12.73M |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.10K | 3.20K | 2.70K | 10.90K | 13.40K |
| Net Income | -3.35M | -3.49M | -7.76M | -77.24M | -12.72M |
| EBIT | -1.55M | -3.21M | -6.61M | -9.78M | -9.64M |
| EBITDA | -1.35M | -3.08M | -6.49M | -9.66M | -9.50M |
| EPS Basic | -0.07 | -0.07 | -0.20 | -2.04 | -0.47 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.13 | -0.09 | -0.25 |
| EPS Diluted | -0.07 | -0.07 | -0.20 | -2.04 | -0.47 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.13 | -0.09 | -0.25 |
| Average Basic Shares Outstanding | 50.23M | 49.67M | 38.26M | 35.11M | 27.04M |
| Average Diluted Shares Outstanding | 50.23M | 49.67M | 38.26M | 35.11M | 27.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |